Hàn Quốc cấp phép khẩn cấp thuốc molnupiravir điều trị COVID-19

Trong nỗ lực giảm ca bệnh nặng và tử vong do COVID-19, cơ quan an toàn dược phẩm của Hàn Quốc ngày 23/3 đã cấp phép khẩn cấp thuốc molnupiravir của hãng Merck & Co Inc để điều trị cho người trưởng thành mắc COVID-19.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh